Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Ltd., a biopharmaceutical company focused on cancer immunotherapies, has confirmed Yrjö Wichmann as their permanent Chief Financial Officer (CFO). Wichmann, with over 20 years of experience in the biotech finance sector, previously held the interim CFO position since April 2024 and served in various senior roles within the company and the industry. This strategic appointment comes as the company advances its lead asset bexmarilimab, a novel immune reprogramming immunotherapy, through clinical trials.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
